Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
9 studies found for:    Ectodermal Dysplasia | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia
Condition: X-Linked Hypohidrotic Ectodermal Dysplasia
Intervention:
2 Recruiting Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Condition: X-Linked Hypohidrotic Ectodermal Dysplasia
Intervention: Drug: EDI200
3 Recruiting Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002
Condition: X-linked Hypohidrotic Ectodermal Dysplasia
Intervention: Drug: EDI200
4 Recruiting Study of Selected X-linked Disorders: Goltz Syndrome
Conditions: Focal Dermal Hypoplasia (FDH);   Goltz Syndrome;   X Linked Disorders
Intervention:
5 Recruiting Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)
Condition: Aplasia Cutis Congenita
Intervention:
6 Unknown  Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita
Condition: Epidermolysis Bullosa Simplex
Interventions: Drug: Dysport® (Botulinumtoxin A (Btx A));   Drug: Placebo
7 Not yet recruiting Simvastatin Treatment of Pachyonychia Congenita
Condition: Pachyonychia Congenita
Intervention: Drug: Simvastatine
8 Recruiting Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC)
Conditions: Pachyonychia Congenita;   Plantar Keratoderma
Intervention: Drug: Topical Sirolimus
9 Recruiting Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
Condition: Pachyonychia Congenita
Interventions: Drug: 1% sirolimus cream (TD201 1%);   Drug: placebo cream (vehicle control)

Indicates status has not been verified in more than two years